title: SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA.
abstract: OBJECTIVE
  The aim of this study to was to evaluate the effect of fibroblast growth factor-23 (FGF-23), osteoprotegerin (OPG), receptor activator nuclear κB ligand (RANKL), and vitamin D hormones on bone loss in patients with hyperprolactinemia due to pituitary prolactinoma.
  
  
  METHODS
  We recruited 46 premenopausal female patients with prolactinoma and age and sex-matched healthy controls (Group 3, n = 20) for this cross-sectional study. Prolactinoma patients were divided into 2 groups as patients newly diagnosed (Group 1, n = 26) and those under cabergoline treatment (Group 2, n = 20). Anthropometric and metabolic variables; hormonal profiles; and osteocalcin, deoxypyridinoline (DOP), and bone mineral density measurements were performed for all participants. FGF-23, OPG, and RANKL levels were analyzed in all groups.
  
  
  RESULTS
  FGF-23, OPG, calcium, phosphorus, and parathormone levels were similar between all groups despite significantly higher levels in the control group in terms of vitamin D and RANKL levels than in patients. Bone loss was found more in Group 2, particularly observed in Z scores of femur and spinal bone (P<.05). Correlation analysis revealed a negative correlation between FGF-23 and femur neck T score (r = -0.0433, P = .05) in patients with active prolactinoma. A positive correlation was also observed between parameters of DOP and OPG (r = 0.673, P = .02). In patients with remission there were a negative correlation between prolactin and luteinizing hormone (r = -600, P = .08). Additionally, a negative correlation was found between osteocalcin and osteoprotegerin in patients in remission (r = -0.73, P = .01).
  
  
  CONCLUSIONS
  Our data indicated that FGF-23 and OPG levels do not play a critical role on the development of bone decrease in patients with hyperprolactinemia. However, further prospective studies in larger numbers of participants should be designed to clarify this issue.
  
  
  BACKGROUND
  BFP = body fat percentage BMD = bone mineral density BMI = body mass index CV = coefficient of variation DOP = deoxypyridinoline ELISA = enzyme-linked immunosorbent assay FGF-23 = fibroblast growth factor-23 HOMA-IR = homeostatic model assessment of insulin resistance OPG = osteoprotegerin RANKL = receptor activator nuclear κB ligand.
authors.forename: Muyesser Sayki
authors.initials: MS
authors.lastname: Arslan
authors.forename: Mustafa
authors.initials: M
authors.lastname: Sahin
authors.forename: Melia
authors.initials: M
authors.lastname: Karakose
authors.forename: Esra
authors.initials: E
authors.lastname: Tutal
authors.forename: Oya
authors.initials: O
authors.lastname: Topaloglu
authors.forename: Bekir
authors.initials: B
authors.lastname: Ucan
authors.forename: Taner
authors.initials: T
authors.lastname: Demirci
authors.forename: Mustafa
authors.initials: M
authors.lastname: Caliskan
authors.forename: Seyda
authors.initials: S
authors.lastname: Ozdemir
authors.forename: Mustafa
authors.initials: M
authors.lastname: Ozbek
authors.forename: Erman
authors.initials: E
authors.lastname: Cakal
mesh_terms: D000328:Adult; D000596:Amino Acids / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D015519:Bone Density; D000077465:Cabergoline; D003430:Cross-Sectional Studies; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D053244:Osteoprotegerin / Q000097:blood*; D010911:Pituitary Neoplasms / Q000097:blood* / Q000188:drug therapy; D015175:Prolactinoma / Q000097:blood* / Q000188:drug therapy; D011446:Prospective Studies; D053245:RANK Ligand / Q000097:blood; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000097:blood*; D014807:Vitamin D / Q000097:blood
chemical_list: D000596:Amino Acids; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004873:Ergolines; C000717427:FGF23 protein, human; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505688:TNFSF11 protein, human; D015675:Osteocalcin; D014807:Vitamin D; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; C036020:deoxypyridinoline; D000077465:Cabergoline